|
INB-200: Phase I study and characterization of gene-modified autologous gamma delta (?d) T cells in newly diagnosed glioblastoma multiforme (GBM). |
| |
|
Consulting or Advisory Role - Anheart Therapeutics; SERVIER |
Patents, Royalties, Other Intellectual Property - Development of novel inhibitors to HuR through NCI funded peer reviewed research. |
Travel, Accommodations, Expenses - SERVIER |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; SpringWorks Therapeutics |
Speakers' Bureau - SpringWorks Therapeutics; SpringWorks Therapeutics |
| |
|
Consulting or Advisory Role - In8Bio Inc. |
| |
|
Employment - Axogen; IN8bio |
Consulting or Advisory Role - Axogen; IN8Bio |
Patents, Royalties, Other Intellectual Property - Pending IP under Axogen. Inc.; Pending IP under Axogen. Inc. |
| |
|
Employment - In8Bio, Inc. |
Stock and Other Ownership Interests - In8Bio Inc. |
| |
|
Employment - IN8Bio, Inc. |
Leadership - IN8Bio, Inc. |
Stock and Other Ownership Interests - IN8Bio, Inc. |
Patents, Royalties, Other Intellectual Property - I receive royalties from intellectual property developed as a Professor of Medicine at the University of Alabama at Birmingham and licensed to my current employer IN8Bio, Inc. |